Clinical trials: Acute Myeloid Leukemia (AML) With
Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia
Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML
This phase 2 clinical trial investigates the effectiveness of cytokine-induced memory-like natural killer (CIML NK) cells in combination with FLAG chemotherapy as a treatment for refractory or relapsed AML.
- Trial name
- NCT04354025
- Testing
- Cytokine induced memory-like NK cells, Fludarabine, Ara-C
- Sponsor
- Washington University School of Medicine
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia
Phase I trial to study the effectiveness of combining oblimersen with cytarabine and daunorubicin in treating older patients who have previously untreated acute myeloid leukemia.
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Trial name
- NCT00039117
- Testing
- oblimersen sodium, cytarabine, daunorubicin hydrochloride
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)
The objective of the phase I part of the trial is the determination of the maximum tolerated dose (MTD) of TCP (Tranylcypromine) in combination with fixed-dose ATRA (all-trans-retinoic acid) and with fixed-dose AraC (Cytarabine)…
- Trial name
- TRANSATRA (NCT02717884)
- Testing
- tranylcypromine, all-trans retinoic acid, cytarabine
- Where
- 6 sites in Germany
- Volunteers
- 60 people
- Sponsor
- Michael Luebbert
Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
This phase II trial is studying the side effects and best dose of alemtuzumab when given together with fludarabine phosphate and total-body irradiation followed by cyclosporine and mycophenolate mofetil in treating patients who…
- Conditions
- Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Trial name
- NCT00118352
- Testing
- alemtuzumab, total-body irradiation, fludarabine phosphate
- Where
- 2 sites in United States, Italy
- Volunteers
- 12 people
- Sponsor
- Fred Hutchinson Cancer Center
Myelodysplastic Syndromes, Acute Myeloid Leukemia
CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
The investigators hypothesize that CX-01 will disrupt the bone marrow microenvironment and increase the cytotoxic effects of azacitidine on myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) hematopoietic stem cells…
- Conditions
- Myelodysplastic Syndromes, Acute Myeloid Leukemia, AML, MDS
- Trial name
- NCT02995655
- Testing
- CX-01, Azacitidine, Bone marrow biopsy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Acute Myeloid Leukemia
Analysis of Biomarkers in Patients With Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Treated With Menin Inhibition.
The white blood cells of patients with acute myeloid leukemia that have undergone allogeneic stem cell transplantation will be investigated. These are patient where the leukemia has returned after the transplantation.
- Trial name
- AML_MenALLO (NCT07627568)
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University of Freiburg
Leukemia
Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well imatinib mesylate works in treating patients with newly…
- Trial name
- NCT00509093
- Testing
- imatinib mesylate, gene expression analysis, mutation analysis
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- Case Comprehensive Cancer Center
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
This phase II trial studies how well pevonedistat works with azacitidine compared to azacitidine alone in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory).
- Trial name
- NCT03745352
- Testing
- Azacitidine, Pevonedistat
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Myelodysplastic Syndrome
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
This research study is studying a drug as a possible treatment for diagnosis of AML, BPDCN and high-risk MDS. The interventions involved in this study are: SL-401 Azacitidine Venetoclax
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm
- Trial name
- NCT03113643
- Testing
- Azacitidine, SL-401, Venetoclax
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- Dana-Farber Cancer Institute
Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is among the most common hematologic malignancies in adults and accounts for approximately 10,000 deaths in the United States every year. AML is commonly diagnosed in sixth or seventh decades of life.
- Conditions
- Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
- Trial name
- NCT03226418
- Testing
- Cytarabine, Decitabine, Idarubicin
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Nebraska
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
The purpose of this study is to understand the safety and estimate the efficacy of combining anti-CD3 x anti-CD33 bispecific antibody (CD33Bi) armed fresh peripheral blood mononuclear cells (CD33Bi FPBMC) for patients with acute…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
- Trial name
- AML-MDS 001 (NCT07270978)
- Testing
- CD33 FPBMC
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Virginia
Acute Myeloid Leukemia
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid…
- Trial name
- NCT06317649
- Testing
- Azacitidine, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 229 sites in United States, Canada and 1 more
- Volunteers
- 147 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
Study of Proteins in Promoting Chemotherapy Resistance in Samples From Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about cancer and development of drug resistance in patients.
- Trial name
- NCT01419496
- Testing
- protein expression analysis, flow cytometry, laboratory biomarker analysis
- Volunteers
- 40 people
- Sponsor
- Children's Oncology Group
Acute Myeloid Leukemia (AML), Non Small Cell Lung Cancer
A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. This study focuses on two types of cancers: Acute Myeloid Leukemia (AML) and Non-Small Cell Lung Cancer (NSCLC).
- Conditions
- Acute Myeloid Leukemia (AML), Non Small Cell Lung Cancer, Cancer
- Trial name
- NCT04272203
- Testing
- ABBV-184
- Where
- 17 sites in United States, France and 3 more
- Volunteers
- 14 people
- Sponsor
- AbbVie
Leukemia
Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
RATIONALE: Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects of panobinostat and to see how well it works in…
- Trial name
- NCT00723203
- Testing
- panobinostat, gene expression analysis, reverse transcriptase-polymerase chain reaction
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- City of Hope Medical Center
Chronic Myeloproliferative Disorders, Leukemia
Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as cyclophosphamide and fludarabine, and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00290641
- Testing
- filgrastim, graft-versus-tumor induction therapy, cyclophosphamide
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Leukemia, Lymphoma
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer
RATIONALE: Biological therapy using growth factors may be effective in reducing side effects in patients who have hematologic cancer and are receiving radiation therapy, chemotherapy, and peripheral stem cell transplantation.
- Conditions
- Leukemia, Lymphoma, Oral Complications
- Trial name
- NCT00004061
- Testing
- filgrastim, palifermin, cyclophosphamide
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Relapsed or Refractory Acute Myeloid Leukemia
Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia
Recent preclinical and retrospective clinical data have suggested that dexamethasone might sensitize leukemic cells to chemotherapy-induced cell death and thus limit the risk of leukemic regrowth and relapse.
- Trial name
- DEXAML-03 (NCT03765541)
- Testing
- Dexamethasone, Amsacrine, Cytarabine
- Where
- 10 sites in France
- Volunteers
- 73 people
- Sponsor
- University Hospital, Toulouse
Acute Myeloid Leukemia (AML)
Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease
A multicenter, open-label, prospective, randomized controlled study to optimize the treatment of patients with acute myeloid leukemia based on early peripheral blood minimal residual disease
- Trial name
- NCT07023588
- Testing
- Venetoclax
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Yehui Tan
Acute Myeloid Leukemia, Adult
Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features
Individualized induction therapy will be applied to the non-elderly acute myeloid leukemia (AML) patients with adverse genetic risk features guided by rapid screening with fluorescence in situ hybridization (FISH) and…
- Trial name
- NCT04752527
- Testing
- venetoclax combined with decitabine
- Where
- China
- Volunteers
- 42 people
- Sponsor
- The First Affiliated Hospital of Soochow University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.